Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471471 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase 1 study, sponsored by Ahmad Tarhini.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00471471 is a Phase 1 study that has completed, run by Ahmad Tarhini. The registered enrollment target is 22 participants.
The verdict
NCT00471471, a Phase 1 study, has completed, sponsored by Ahmad Tarhini.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
Interventions
- BIOLOGICAL Peptide vaccine
- BIOLOGICAL GM-CSF
- BIOLOGICAL PF3512676
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471471
The ClinicalTrials.gov registry entry for NCT00471471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ahmad Tarhini, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Peptide vaccine is the first listed.
NCT00471471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471471 about?
NCT00471471 is a clinical study titled "Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is stu...
What is the current status of trial NCT00471471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00471471?
The interventions under investigation include: Peptide vaccine (BIOLOGICAL), GM-CSF (BIOLOGICAL), PF3512676 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00471471?
This trial is sponsored by Ahmad Tarhini, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.